Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis

Ali Zaid, Nestor Rulli, Michael Rolph, Andreas Suhrbier, Suresh Mahalingam

    Research output: Contribution to journalArticle

    25 Citations (Scopus)

    Abstract

    OBJECTIVE: Mosquito-borne alphaviruses such as chikungunya virus, O'nyong-nyong virus and Ross River virus (RRV) cause sporadic, sometimes large, outbreaks of rheumatic disease worldwide. Here we test the effect of treating RRV-induced arthritis using the anti-TNF drug, etanercept, in a mouse model of rheumatic disease. METHODS: Mice were infected with RRV and treated with etanercept. Weight loss, tissue viral titers and histological examination of muscle and joint tissues were undertaken. RESULTS: RRV-infected mice treated with etanercept showed increased weight loss, higher viral titres in muscle, joints and blood, more tissue damage and inflammatory cell recruitment than RRV-infected mice without treatment. CONCLUSION: Anti-TNF therapy is unlikely to have utility in treating alphaviral arthritides. During alphaviral epidemics careful monitoring of patients being treated with anti-TNF drugs may be warranted.
    Original languageEnglish
    Pages (from-to)488-491
    Number of pages4
    JournalArthritis and Rheumatism (Online)
    Volume63
    Issue number2
    DOIs
    Publication statusPublished - 2011

    Fingerprint

    Ross River virus
    Myositis
    Arthritis
    Disease Progression
    Rheumatic Diseases
    O'nyong-nyong Virus
    Weight Loss
    Joints
    Chikungunya virus
    Alphavirus
    Muscles
    Physiologic Monitoring
    Culicidae
    Pharmaceutical Preparations
    Disease Outbreaks
    Etanercept

    Cite this

    Zaid, Ali ; Rulli, Nestor ; Rolph, Michael ; Suhrbier, Andreas ; Mahalingam, Suresh. / Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis. In: Arthritis and Rheumatism (Online). 2011 ; Vol. 63, No. 2. pp. 488-491.
    @article{ea3d5be854f1428c854a7e4bdf0f0ca3,
    title = "Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis",
    abstract = "OBJECTIVE: Mosquito-borne alphaviruses such as chikungunya virus, O'nyong-nyong virus and Ross River virus (RRV) cause sporadic, sometimes large, outbreaks of rheumatic disease worldwide. Here we test the effect of treating RRV-induced arthritis using the anti-TNF drug, etanercept, in a mouse model of rheumatic disease. METHODS: Mice were infected with RRV and treated with etanercept. Weight loss, tissue viral titers and histological examination of muscle and joint tissues were undertaken. RESULTS: RRV-infected mice treated with etanercept showed increased weight loss, higher viral titres in muscle, joints and blood, more tissue damage and inflammatory cell recruitment than RRV-infected mice without treatment. CONCLUSION: Anti-TNF therapy is unlikely to have utility in treating alphaviral arthritides. During alphaviral epidemics careful monitoring of patients being treated with anti-TNF drugs may be warranted.",
    keywords = "mosquito-borne alphaviruses, rheumatic disease, etanercept, anti-tumor necrosis factor, anti-TNF, RRV",
    author = "Ali Zaid and Nestor Rulli and Michael Rolph and Andreas Suhrbier and Suresh Mahalingam",
    year = "2011",
    doi = "10.1002/ART.30112",
    language = "English",
    volume = "63",
    pages = "488--491",
    journal = "Arthritis Rheumatism",
    issn = "0004-3591",
    publisher = "John Wiley & Sons",
    number = "2",

    }

    Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis. / Zaid, Ali; Rulli, Nestor; Rolph, Michael; Suhrbier, Andreas; Mahalingam, Suresh.

    In: Arthritis and Rheumatism (Online), Vol. 63, No. 2, 2011, p. 488-491.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis

    AU - Zaid, Ali

    AU - Rulli, Nestor

    AU - Rolph, Michael

    AU - Suhrbier, Andreas

    AU - Mahalingam, Suresh

    PY - 2011

    Y1 - 2011

    N2 - OBJECTIVE: Mosquito-borne alphaviruses such as chikungunya virus, O'nyong-nyong virus and Ross River virus (RRV) cause sporadic, sometimes large, outbreaks of rheumatic disease worldwide. Here we test the effect of treating RRV-induced arthritis using the anti-TNF drug, etanercept, in a mouse model of rheumatic disease. METHODS: Mice were infected with RRV and treated with etanercept. Weight loss, tissue viral titers and histological examination of muscle and joint tissues were undertaken. RESULTS: RRV-infected mice treated with etanercept showed increased weight loss, higher viral titres in muscle, joints and blood, more tissue damage and inflammatory cell recruitment than RRV-infected mice without treatment. CONCLUSION: Anti-TNF therapy is unlikely to have utility in treating alphaviral arthritides. During alphaviral epidemics careful monitoring of patients being treated with anti-TNF drugs may be warranted.

    AB - OBJECTIVE: Mosquito-borne alphaviruses such as chikungunya virus, O'nyong-nyong virus and Ross River virus (RRV) cause sporadic, sometimes large, outbreaks of rheumatic disease worldwide. Here we test the effect of treating RRV-induced arthritis using the anti-TNF drug, etanercept, in a mouse model of rheumatic disease. METHODS: Mice were infected with RRV and treated with etanercept. Weight loss, tissue viral titers and histological examination of muscle and joint tissues were undertaken. RESULTS: RRV-infected mice treated with etanercept showed increased weight loss, higher viral titres in muscle, joints and blood, more tissue damage and inflammatory cell recruitment than RRV-infected mice without treatment. CONCLUSION: Anti-TNF therapy is unlikely to have utility in treating alphaviral arthritides. During alphaviral epidemics careful monitoring of patients being treated with anti-TNF drugs may be warranted.

    KW - mosquito-borne alphaviruses

    KW - rheumatic disease

    KW - etanercept

    KW - anti-tumor necrosis factor

    KW - anti-TNF

    KW - RRV

    U2 - 10.1002/ART.30112

    DO - 10.1002/ART.30112

    M3 - Article

    VL - 63

    SP - 488

    EP - 491

    JO - Arthritis Rheumatism

    JF - Arthritis Rheumatism

    SN - 0004-3591

    IS - 2

    ER -